Cargando…

Hepatocellular carcinomas: evolution to sorafenib resistance through hepatic leukaemia factor

Detalles Bibliográficos
Autores principales:	Musso, Orlando, Beraza, Naiara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6839724/ https://www.ncbi.nlm.nih.gov/pubmed/31270163 http://dx.doi.org/10.1136/gutjnl-2019-318999

Ejemplares similares

The synergistic effect of sorafenib and TNF-α inhibitor on hepatocellular carcinoma
por: Wang, Mingda, et al.
Publicado: (2019)

Overcoming sorafenib treatment-resistance in hepatocellular carcinoma: A future perspective at a time of rapidly changing treatment paradigms
por: Chen, Jiang, et al.
Publicado: (2020)

Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?
por: Shing, Kit, et al.
Publicado: (2020)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

Predicting the response to sorafenib in hepatocellular carcinoma: where is the evidence for phosphorylated extracellular signaling-regulated kinase (pERK)?
por: Zhu, Andrew X
Publicado: (2009)

MRP3 as a novel resistance factor for sorafenib in hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2016)

Orlistat Resensitizes Sorafenib-Resistance in Hepatocellular Carcinoma Cells through Modulating Metabolism
por: Shueng, Pei-Wei, et al.
Publicado: (2022)

Sorafenib Resistance in Hepatocellular Carcinoma: The Relevance of Genetic Heterogeneity
por: Cabral, Loraine Kay D., et al.
Publicado: (2020)

The microenvironmental and metabolic aspects of sorafenib resistance in hepatocellular carcinoma
por: Xia, Shunjie, et al.
Publicado: (2020)

Autophagy and biotransformation affect sorafenib resistance in hepatocellular carcinoma
por: Zheng, Ruiqi, et al.
Publicado: (2023)

Sorafenib plus hepatic arterial infusion chemotherapy with oxaliplatin versus sorafenib alone for advanced hepatocellular carcinoma
por: Zhao, Yang, et al.
Publicado: (2019)

Multikinase inhibitors to treat hepatocellular carcinoma failures to sorafenib—time has come for a better approach
por: Alqahtani, Saleh A., et al.
Publicado: (2020)

Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma
por: Kuczynski, Elizabeth A., et al.
Publicado: (2016)

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
por: Hu, Xinyao, et al.
Publicado: (2021)

Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
por: Shi, Tingting, et al.
Publicado: (2021)

PARP inhibitor Olaparib overcomes Sorafenib resistance through reshaping the pluripotent transcriptome in hepatocellular carcinoma
por: Yang, Xiao-Dong, et al.
Publicado: (2021)

Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Mousa, Ali Ben
Publicado: (2008)

Sorafenib for the treatment of unresectable hepatocellular carcinoma
por: Furuse, Junji
Publicado: (2008)

Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
por: Sanoff, Hanna K., et al.
Publicado: (2016)

Optimizing outcomes in HCC: Comment on “optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis” by Jiang et al.
por: Rizzo, Alessandro
Publicado: (2021)

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2019)

AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest
por: Zhou, Wei, et al.
Publicado: (2021)

Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
por: Lai, You-Liang, et al.
Publicado: (2022)

The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
por: Chow, Ariel Ka-Man, et al.
Publicado: (2013)

Rage induces hepatocellular carcinoma proliferation and sorafenib resistance by modulating autophagy
por: Li, Jun, et al.
Publicado: (2018)

The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects
por: Tang, Weiwei, et al.
Publicado: (2020)

Exploring the mechanism of resistance to sorafenib in two hepatocellular carcinoma cell lines
por: Zhang, Zhi, et al.
Publicado: (2020)

LY3214996 relieves acquired resistance to sorafenib in hepatocellular carcinoma cells
por: Ma, Yongfang, et al.
Publicado: (2021)

Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
por: Zhu, Qiankun, et al.
Publicado: (2020)

Targeted inhibition of ACLY expression to reverse the resistance of sorafenib in hepatocellular carcinoma
por: Sun, Hong, et al.
Publicado: (2022)

Link of sorafenib resistance with the tumor microenvironment in hepatocellular carcinoma: Mechanistic insights
por: Tian, Xinchen, et al.
Publicado: (2022)

CASK Silence Overcomes Sorafenib Resistance of Hepatocellular Carcinoma Through Activating Apoptosis and Autophagic Cell Death
por: Ding, Bisha, et al.
Publicado: (2021)

Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: randomized phase II trial
por: Ikeda, M., et al.
Publicado: (2016)

Sorafenib Rechallenge and Sorafenib after Lenvatinib Failure in a Patient with Hepatocellular Carcinoma
por: Ikeda, Atsuyuki, et al.
Publicado: (2021)

Association Between Hepatitis C and Hepatocellular Carcinoma
por: de Oliveria Andrade, Luis Jesuino, et al.
Publicado: (2009)

Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus
por: Zhang, Yong-Fa, et al.
Publicado: (2016)

Treatment strategies for advanced hepatocellular carcinoma: Sorafenib vs hepatic arterial infusion chemotherapy
por: Saeki, Issei, et al.
Publicado: (2018)

Sorafenib combined with embolization plus hepatic arterial infusion chemotherapy for inoperable hepatocellular carcinoma
por: Liu, Bao-Jiang, et al.
Publicado: (2020)

Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure
por: Li, Xiaomi, et al.
Publicado: (2022)

Risk Factors for Hepatic Encephalopathy in Hepatocellular Carcinoma After Sorafenib or Lenvatinib Treatment: A Real-World Study
por: Chen, Bowen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_47t37bjm8vja94upa485svc2v3